succimer

Trade name: Chemet

Small moleculeapproved

Approved

May 18, 1982

Succimer, sold under the brand name Chemet among others, is a medication tool used to treat lead, mercury, and arsenic poisoning. When it's radiolabeled with technetium-99m, it's used in many types of diagnostic testing. — Wikipedia

Clinical trial activity

7 trials · 7 clinical orgs · 3 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Jul 15, 1994 (NCT00342849)

Timeline

1980s

  1. May 18, 1982

    Earliest FDA Approval

  2. May 18, 1982

    General Electric — NDA Secondary Org

1990s

  1. Jan 30, 1991

    Recordati — First NDA Organization

  2. Jan 30, 1991

    Recordati — NDA Secondary Org

  3. Jan 30, 1991

    Recordati — NDA Organization

  4. Jan 1, 1994

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Feb 18, 2022

    Theragnostics Ltd — Marketing Organization

  2. Feb 18, 2022

    Theragnostics Ltd — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedMay 18, 1982

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O)[C@@H](S)[C@@H](S)C(=O)O
Mol. weight
280.22 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2,3-dimercaptosuccinic acid
  • 2,3-dimercaptosuccinic acid
  • chemet
  • chemet
  • chemet
  • dimercaptosuccinic acid
  • dimercaptosuccinic acid
  • dimercaptosuccinic acid
  • dimercaptosuccinic acid
  • dim-sa
  • dim-sa
  • dmsa
  • dmsa
  • dmsa
  • dmsa
  • dmsa kidney reagent
  • dmsa kidney reagent
  • meso-2,3-dimercaptobernsteinsäure
  • meso-2,3-dimercaptobernsteinsäure
  • meso-2,3-dimercaptosuccinic acid
  • meso-2,3-dimercaptosuccinic acid
  • meso-2,3-dimercaptosuccinic acid
  • meso-dimercaptosuccinic acid
  • meso-dimercaptosuccinic acid
  • meso-dimercaptosuccinic acid
  • mpi dmsa kidney reagent
  • mpi dmsa kidney reagent
  • mpi dmsa kidney reagent
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • succimer
  • technetium (99mtc) dimercaptosuccinic acid for injection
  • technetium (99mtc) succimer
  • technetium succimer
  • technetium succimer
  • technetium tc 99m succimer
  • technetium tc 99m succimer
  • technetium tc-99m succimer
  • technetium tc-99m succimer
  • technetium tc-99m succimer kit
  • technetium tc-99m succimer kit

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06811233Phase 2May 8, 2025University of Texas at Houston
NCT03957720Early Phase 1 (Phase 1)Mar 15, 2019Zhejiang University
NCT03630991Phase 2Oct 31, 2018University of Texas at Houston
NCT00376194Phase 2Sep 1, 2006National Institute of Mental Health (NIMH)
NCT00811083Phase 1/Phase 2 (Phase 2)May 1, 2005Southwest College of Naturopathic Medicine
NCT00004838N/ASep 1, 1997National Institutes of Health (NIH), Ohio State University
NCT00342849Phase 3Jul 15, 1994National Institute of Environmental Health Sciences (NIEHS)
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of Texas at HoustonAcademic/Hospital2212018
National Institute of Environmental Health Sciences (NIEHS)Government1111994
National Institute of Mental Health (NIMH)Government1112006
National Institutes of Health (NIH)Government1111997
Ohio State UniversityAcademic/Hospital1011997
Southwest College of Naturopathic MedicineAcademic/Hospital1112005
Zhejiang UniversityAcademic/Hospital1112019
7 organizations
Page 1 / 1

Marketing (5)

OrganizationOrg typeRelationshipDate
General ElectricFor profitNDA2May 18, 1982
RecordatiFor profitNDA2Jan 30, 1991
RecordatiFor profitNDAJan 30, 1991
Theragnostics LtdFor profitMKTGFeb 18, 2022
Theragnostics LtdFor profitNDA2Feb 18, 2022